Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 9, 2010, Pages 1106-1110

  Ozenne, Violaine ^a   Paradis, Valerie ^a   Pernot, Simon ^a   Castelnau, Corinne ^a   Vullierme, Marie Pierre ^a   Bouattour, Mohamed ^a   Valla, Dominique ^a   Farges, Olivier ^a   Degos, Françoise ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Keywordshepatocellular carcinoma; Prognostic markers; Side effects; Sorafenib; Tolerance

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; SORAFENIB;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOGRAPHY; RETROSPECTIVE STUDY; SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PYRIDINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78349275393     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283386053     Document Type: Article

References (19)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
6. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359:1995-2004.
7. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004; 3:73-81.
8. Llovet JPC, Shan M, Jeffers M, Lathia C, Bruix J. Biomarkers predicting outcome of patients with hepatocelluar carcinoma: results from the randomized Phase III SHARP trial. Hepatology 2008; 48 (Suppl 1):372A.
9. LLovet J PC, Shan M, Lathia C, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma: results from the randomized Phase III SHARP trial. J Hepatol 2009; 50 (Suppl 1):S385.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
11. Therasse PAS, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, et al. New guidelines to evaluate the response to treatment in solid tumors. J National Cancer Institute 2000; 92:205-216.
12. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14:70-76.
13. Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43:489-495.
14. Romano OCS, Dharancy S, Canva V, Castel H, Boleslawski E, Truant S, et al. Prospective evaluation of sorafenib (so) in patients with hepatocellular carcinoma (HCC): does Child score B influence safety? J Hepatol 2009; 50 (Suppl 1):S28.
15. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49:138-151.
16. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008; 14:3850-3859.
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
18. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60:151-170.
19. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9:5339-5345.